EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual-mode hepatoprotective nanoplatform combines ROS scavenging and FGF21 activation for precision acute liver injury therapy

Xinyu Tan, Man Li, Zhibin Lan, Wenxiang Zhang, Junjie Zou, Yibo An, Jingwen Zheng, Xuwen Xiang, Jing Lin, Sheng Lin, Wenjie Ni, Lin Che und 3 weitere

Acta Pharmaceutica Sinica B · 2026-11 · 16 (11) · 7744-7765

DOI: 10.1016/j.apsb.2026.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Xinyu Tan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Health, Department of Pediatrics, Women and Children's Hospital, School of Life Sciences, Xiamen University, Xiamen 361102, China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Xiamen Municipality, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Acute liver injuryAnti-inflammatoryDiselenide-bridged mesoporous silica nanosystemFGF21Multidimensional therapeutic strategyPrecise deliveryReactive oxygen speciesSilymarin

Autor:innen und Institutionen

  • Department of Child Health, Department of Pediatrics, Women and Children's Hospital, School of Life Sciences, Xiamen University, Xiamen 361102, China.
  • State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiame…
  • Sichuan Research Institute of Xiamen University, Chengdu 610000, China.
  • Fuzhou University Affiliated Provincial Hospital, School of Medicine, Fuzhou University, Fuzhou 350108, China.
  • State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory…
  • State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou National Laboratory, Guangzhou 510005, China.

Förderung

  • Natural Science Foundation of Xiamen Municipality
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Medical Innovation Project of Fujian Province
  • Natural Science Foundation of Sichuan Province
  • Natural Science Foundation of Fujian Province
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Tan, X., Li, M., Lan, Z., Zhang, W., Zou, J., An, Y., Zheng, J., Xiang, X., Lin, J., Lin, S., Ni, W., Che, L., Liu, G., Chen, J., & Lu, Z. (2026). Dual-mode hepatoprotective nanoplatform combines ROS scavenging and FGF21 activation for precision acute liver injury therapy. Acta Pharmaceutica Sinica B, 16(11), 7744-7765. https://doi.org/10.1016/j.apsb.2026.03.005

Vancouver

Tan X, Li M, Lan Z, Zhang W, Zou J, An Y, et al. Dual-mode hepatoprotective nanoplatform combines ROS scavenging and FGF21 activation for precision acute liver injury therapy. Acta Pharmaceutica Sinica B. 2026;16(11):7744-7765. doi:10.1016/j.apsb.2026.03.005

BibTeX
@article{Tan2026,
  author = {Tan, Xinyu and Li, Man and Lan, Zhibin and Zhang, Wenxiang and Zou, Junjie and An, Yibo and Zheng, Jingwen and Xiang, Xuwen and Lin, Jing and Lin, Sheng and Ni, Wenjie and Che, Lin and Liu, Gang and Chen, Jing and Lu, Zhixiang},
  title = {Dual-mode hepatoprotective nanoplatform combines ROS scavenging and FGF21 activation for precision acute liver injury therapy},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {7744--7765},
  doi = {10.1016/j.apsb.2026.03.005}
}
Kostenlos starten →